Company / Current Liabilities
Altimmune, Inc. Current Liabilities History
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$15.0M
FY2025
5-year range
$10.5M / $18.3M
FY2021-FY2025
Trend
+43.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities returned to growth in FY2025 after 3 years of decline, reaching $15M.
Based on SEC 10-K filings.
$15M in FY2025 with a 5-year CAGR of +4.5%.
Increased from $12M to $15M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -4.2%
- 5-Year CAGR
- +4.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +4.5%, indicating consistent growth.
- In FY2025, current liabilities increased 43.3% year-over-year.
- Peak current liabilities was recorded in FY2021.
- Lowest current liabilities in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score -0.62 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $15.0M | +43.3% |
| FY2024 | $10.5M | -13.8% |
| FY2023 | $12.1M | -28.8% |
| FY2022 | $17.1M | -6.7% |
| FY2021 | $18.3M | +52.0% |
| FY2020 | $12.0M | +206.4% |
| FY2019 | $3.9M | -13.3% |
| FY2018 | $4.5M | +17.9% |
| FY2017 | $3.8M | -16.8% |
| FY2011 | $4.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026